Literature DB >> 19321602

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Zhen-yong Keck1, Sophia H Li, Jinming Xia, Thomas von Hahn, Peter Balfe, Jane A McKeating, Jeroen Witteveldt, Arvind H Patel, Harvey Alter, Charles M Rice, Steven K H Foung.   

Abstract

Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis C virus (HCV) infection. To elucidate possible mechanisms of virus escape from these antibodies, retrovirus particles pseudotyped with HCV glycoproteins (HCVpp) isolated from sequential samples collected over a 26-year period from a chronically infected patient, H, were used to characterize the neutralization potential and binding affinity of a panel of anti-HCV E2 human monoclonal antibodies (HMAbs). Moreover, AP33, a neutralizing murine monoclonal antibody (MAb) to a linear epitope in E2, was also tested against selected variants. The HMAbs used were previously shown to broadly neutralize HCV and to recognize a cluster of highly immunogenic overlapping epitopes, designated domain B, containing residues that are also critical for binding of viral E2 glycoprotein to CD81, a receptor essential for virus entry. Escape variants were observed at different time points with some of the HMAbs. Other HMAbs neutralized all variants except for the isolate 02.E10, obtained in 2002, which was also resistant to MAb AP33. The 02.E10 HCVpp that have reduced binding affinities for all antibodies and for CD81 also showed reduced infectivity. Comparison of the 02.E10 nucleotide sequence with that of the strain H-derived consensus variant, H77c, revealed the former to have two mutations in E2, S501N and V506A, located outside the known CD81 binding sites. Substitution A506V in 02.E10 HCVpp restored binding to CD81, but its antibody neutralization sensitivity was only partially restored. Double substitutions comprising N501S and A506V synergistically restored 02.E10 HCVpp infectivity. Other mutations that are not part of the antibody binding epitope in the context of N501S and A506V were able to completely restore neutralization sensitivity. These findings showed that some nonlinear overlapping epitopes are more essential than others for viral fitness and consequently are more invariant during earlier years of chronic infection. Further, the ability of the 02.E10 consensus variant to escape neutralization by the tested antibodies could be a new mechanism of virus escape from immune containment. Mutations that are outside receptor binding sites resulted in structural changes leading to complete escape from domain B neutralizing antibodies, while simultaneously compromising viral fitness by reducing binding to CD81.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321602      PMCID: PMC2687388          DOI: 10.1128/JVI.00248-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.

Authors:  Tobias Allander; Katarina Drakenberg; Aster Beyene; Domenico Rosa; Sergio Abrignani; Michael Houghton; Anders Widell; Lena Grillner; Mats A A Persson
Journal:  J Gen Virol       Date:  2000-10       Impact factor: 3.891

Review 2.  Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.

Authors:  J Bukh; R H Miller; R H Purcell
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

3.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

4.  Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.

Authors:  U Kumar; J Monjardino; H C Thomas
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

5.  Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.

Authors:  R Thomssen; S Bonk; A Thiele
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

6.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

Authors:  D Rosa; S Campagnoli; C Moretto; E Guenzi; L Cousens; M Chin; C Dong; A J Weiner; J Y Lau; Q L Choo; D Chien; P Pileri; M Houghton; S Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

8.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Effect of immune globulin on the prevention of experimental hepatitis C virus infection.

Authors:  K Krawczynski; M J Alter; D L Tankersley; M Beach; B H Robertson; S Lambert; G Kuo; J E Spelbring; E Meeks; S Sinha; D A Carson
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

10.  Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.

Authors:  Y K Shimizu; M Hijikata; A Iwamoto; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more
  60 in total

1.  Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

Review 2.  Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection.

Authors:  Ernest T Chivero; Jack T Stapleton
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

3.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

4.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 5.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 6.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

7.  Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Authors:  Valerie J Kinchen; Muhammad N Zahid; Andrew I Flyak; Mary G Soliman; Gerald H Learn; Shuyi Wang; Edgar Davidson; Benjamin J Doranz; Stuart C Ray; Andrea L Cox; James E Crowe; Pamela J Bjorkman; George M Shaw; Justin R Bailey
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

8.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

Review 9.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.